Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorTing YANG
About this trial
This study is a prospective cohort study. The case group will include patients with primary central nervous system lymphoma confirmed by imaging and pathology. The control group will include patients with pathologically confirmed diffuse large B-cell lymphoma who have been excluded from central nervous system involvement, as well as age- and gender-matched healthy volunteers (hematopoietic stem cell donors). Baseline data (as described below) will be collected. Patients with primary CNS lymphoma will undergo follow-up every 3 months, with immediate follow-up if clinical symptoms arise.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Aged between 18 and 75 years.
The case group must have a confirmed diagnosis of primary central nervous system lymphoma (PCNSL) and must not have received any antitumor therapy prior to baseline sample collection.
Must sign an informed consent form, agree to participate in this study, and provide samples and clinical information as required.
Case group patients must have complete supporting imaging and pathology data.
Disqualifiers
Presence of other systemic malignancies.
Presence of severe infections or metabolic disorders.
Use of antimetabolites or chemotherapy drugs within one week prior to sample collection.
Pregnant or lactating women.
Trial population
Hematopoietic stem cell donor
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
20 Participants
are grouped into 4 trial groupsGroup A: PCNSL
Group B: GDLBCL
Group C: DLBCL
Group D: Health
Trial outcomes
Primary outcomes
1
Metabolomics
Detection of metabolites in plasma using liquid chromatography-mass spectrometry (LC-MS) technology
Time frame
Before the start of the first treatment cycle, at the end of each treatment cycle(each cycle is 28 days)2
CYTOF
Immunophenotyping of PBMCs using flow cytometry mass spectrometry (CYTOF)
Time frame
Before the start of the first treatment cycle, at the end of each treatment cycle(each cycle is 28 days)Secondary outcomes
1
OS
Overall survival
Time frame
From date of randomization until the date of the end of follow-up or date of death from any cause, whichever came first, assessed up to 12months2
PFS
Progression-free survival
Time frame
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Ting YANG
Lead sponsor
Fujian Medical University
Sponsor institution
Source ClinicalTrials.gov